Ulka Vaishampayan, MD: Moving on to the upcoming studies in the second-line setting, I am going to discuss the CANTATA study. This trial is probably the closest to reporting out results. The study is a combination of cabozantinib with or without CB-839 [glutaminase inhibitor]. Again, this is a double-blinded, placebo-controlled trial. CB-839 [glutaminase inhibitor] is a glutaminase inhibitor that has shown synergy with cabozantinib. The primary end point of this study is progression-free survival [PFS]. Hopefully, we will see positive results soon. Overall, the toxicity of the combination appears to be well tolerated, because there were no changes in the study midstream. And the study has completed accrual.

The other novel agents that are being looked at—1, of course, that is in the forefront is the HIF-2alpha inhibitor, PT2977. PT2977 was recently reported in a clinical trial in combination with pembrolizumab. Dr Toni Choueiri reported this at GU ASCO [Genitourinary Cancers Symposium] 2020, and fairly promising response rates and efficacy were noted.

The other treatments that are being looked at in clinical trials are novel agents like CXCR4 inhibitors. There is also a multitargeted tyrosine kinase inhibitor named sitravatinib. Along with nivolumab, it showed a promising rate of PFS in pretreated patients with metastatic kidney cancer.

Transcript Edited for Clarity